Thus, clearance of Tau seeds by immunization with Tau antibodies could provide a potential therapeutic opportunity to block the spread of the pathology in Alzheimer’s disease (AD) and other tauopathies. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.